Total Payments
$4,842
2024 Payments
$14.68
Companies
33
Transactions
243
Medicare Patients
1,982
Medicare Billing
$404,993
Payment Breakdown by Category
Food & Beverage$4,730 (97.7%)
Consulting$100.00 (2.1%)
Education$12.02 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,730 | 240 | 97.7% |
| Consulting Fee | $100.00 | 1 | 2.1% |
| Education | $12.02 | 2 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $1,105 | 60 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $582.37 | 17 | $0 (2019) |
| GlaxoSmithKline, LLC. | $425.49 | 19 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $378.72 | 24 | $0 (2019) |
| PFIZER INC. | $343.95 | 15 | $0 (2019) |
| Allergan Inc. | $323.48 | 23 | $0 (2019) |
| Janssen Pharmaceuticals, Inc | $277.29 | 16 | $0 (2021) |
| Lilly USA, LLC | $179.09 | 12 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $177.18 | 7 | $0 (2019) |
| AbbVie Inc. | $142.77 | 8 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $14.68 | 1 | Insmed, Inc. ($14.68) |
| 2022 | $30.71 | 1 | Melinta Therapeutics, LLC ($30.71) |
| 2021 | $265.36 | 10 | AbbVie Inc. ($128.26) |
| 2019 | $1,546 | 67 | Novo Nordisk Inc ($370.89) |
| 2018 | $1,794 | 86 | GlaxoSmithKline, LLC. ($350.26) |
| 2017 | $1,191 | 78 | Novo Nordisk Inc ($399.47) |
All Payment Transactions
243 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/01/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $14.68 | General |
| Category: Respiratory | ||||||
| 04/22/2022 | Melinta Therapeutics, LLC | Vabomere (Drug), Orbactiv | Food and Beverage | In-kind items and services | $30.71 | General |
| Category: ANTIBIOTICS | ||||||
| 11/09/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $64.88 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/15/2021 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv, Vabomere | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: ANTIBIOTICS | ||||||
| 09/24/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $98.78 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/16/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $2.14 | General |
| Category: NEUROSCIENCE | ||||||
| 09/15/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: NEUROSCIENCE | ||||||
| 09/03/2021 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $12.46 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 09/01/2021 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/17/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $4.81 | General |
| Category: NEUROSCIENCE | ||||||
| 07/30/2021 | AbbVie Inc. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.98 | General |
| Category: NEUROSCIENCE | ||||||
| 07/23/2021 | AbbVie Inc. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $12.78 | General |
| Category: NEUROSCIENCE | ||||||
| 12/19/2019 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/18/2019 | Genentech USA, Inc. | Xofluza (Drug) | Food and Beverage | In-kind items and services | $81.89 | General |
| Category: Virology & Specialty Care | ||||||
| 12/17/2019 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $2.33 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/13/2019 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $19.00 | General |
| Category: Respiratory | ||||||
| 12/12/2019 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $60.95 | General |
| Category: Cardiovascular | ||||||
| 12/12/2019 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $3.60 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/22/2019 | Amarin Pharma Inc. | Vascepa (Drug) | Food and Beverage | In-kind items and services | $11.12 | General |
| Category: Hypertriglyceridemia | ||||||
| 11/21/2019 | PFIZER INC. | EUCRISA (Drug) | Food and Beverage | In-kind items and services | $54.50 | General |
| Category: DERMATOLOGY | ||||||
| 11/15/2019 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $21.28 | General |
| Category: Diabetes | ||||||
| 11/13/2019 | PFIZER INC. | CHANTIX (Drug), EUCRISA, COLOGUARD | Food and Beverage | In-kind items and services | $12.90 | General |
| Category: NEUROSCIENCE;TOBACCO DEPENDENCE | ||||||
| 11/07/2019 | PFIZER INC. | COLOGUARD (Device) | Food and Beverage | In-kind items and services | $101.08 | General |
| Category: GASTROINTESTINAL | ||||||
| 11/06/2019 | Allergan Inc. | LINZESS (Drug) | Food and Beverage | In-kind items and services | $73.62 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/31/2019 | Allergan Inc. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $4.00 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 442 | 1,141 | $389,238 | $98,818 |
| 2022 | 5 | 464 | 1,298 | $277,724 | $87,985 |
| 2021 | 5 | 442 | 1,385 | $277,512 | $96,681 |
| 2020 | 6 | 634 | 1,997 | $375,204 | $121,509 |
Total Patients
1,982
Total Services
5,821
Medicare Billing
$404,993
Procedure Codes
22
All Medicare Procedures & Services
22 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 185 | 702 | $202,176 | $61,559 | 30.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 187 | 208 | $115,856 | $26,641 | 23.0% |
| 11042 | Removal of skin and tissue, 20.0 sq cm or less | Facility | 2023 | 22 | 125 | $45,750 | $5,014 | 11.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 18 | 56 | $14,336 | $2,672 | 18.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 30 | $6,000 | $1,606 | 26.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 13 | 20 | $5,120 | $1,326 | 25.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 199 | 893 | $140,201 | $47,558 | 33.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 200 | 222 | $96,570 | $32,281 | 33.4% |
| 11042 | Removal of skin and tissue, 20.0 sq cm or less | Facility | 2022 | 21 | 113 | $29,041 | $4,563 | 15.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 32 | 58 | $9,164 | $2,833 | 30.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 12 | 12 | $2,748 | $749.61 | 27.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 207 | 1,111 | $174,427 | $60,806 | 34.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 177 | 199 | $86,565 | $30,290 | 35.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 21 | 24 | $7,056 | $2,478 | 35.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 22 | 32 | $5,056 | $1,654 | 32.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 19 | $4,408 | $1,454 | 33.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 257 | 1,418 | $222,626 | $73,982 | 33.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 186 | 200 | $87,000 | $29,150 | 33.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 95 | 103 | $30,282 | $9,880 | 32.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 62 | 194 | $16,490 | $5,343 | 32.4% |
| 11042 | Removal of skin and tissue first 20 sq cm or less | Facility | 2020 | 23 | 68 | $17,476 | $2,899 | 16.6% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Facility | 2020 | 11 | 14 | $1,330 | $255.35 | 19.2% |
About Paul Gobbo
Paul Gobbo is a Infectious Disease healthcare provider based in Lincoln, Nebraska. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144383449.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Paul Gobbo has received a total of $4,842 in payments from pharmaceutical and medical device companies, with $14.68 received in 2024. These payments were reported across 243 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($4,730).
As a Medicare-enrolled provider, Gobbo has provided services to 1,982 Medicare beneficiaries, totaling 5,821 services with total Medicare billing of $404,993. Data is available for 4 years (2020–2023), covering 22 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Other Specialties Internal Medicine
- Location Lincoln, NE
- Active Since 12/18/2006
- Last Updated 04/12/2011
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1144383449
Products in Payments
- Victoza (Drug) $395.85
- Ozempic (Drug) $329.85
- FARXIGA (Drug) $317.70
- BYDUREON (Drug) $251.12
- XARELTO (Drug) $249.24
- Tresiba (Drug) $208.13
- ZERBAXA (Drug) $201.79
- JARDIANCE (Drug) $189.78
- TRULICITY (Drug) $166.49
- ANORO (Drug) $166.00
- BYSTOLIC (Drug) $146.41
- SHINGRIX (Biological) $127.46
- CHANTIX (Drug) $126.54
- LINZESS (Drug) $119.77
- TRELEGY ELLIPTA (Drug) $101.93
- COLOGUARD (Device) $101.08
- DALVANCE (Drug) $90.00
- ISENTRESS (Drug) $86.00
- Saxenda (Drug) $81.94
- Xofluza (Drug) $81.89
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Lincoln
Dr. Steven Rademacher, Md, MD
Infectious Disease — Payments: $1,636
Infectious Disease $1,636
Dr. Daniel Smith, M.d, M.D
Infectious Disease — Payments: $969.85
Infectious Disease $969.85
Dr. James Nora, Md, MD
Infectious Disease — Payments: $217.25
Infectious Disease $217.25
Dr. Thomas Safranek, M.d, M.D
Infectious Disease — Payments: $58.66
Infectious Disease $58.66
Richard Morin, Md, MD
Infectious Disease
Infectious Disease
Dr. Thomas Stalder, M.d, M.D
Infectious Disease
Infectious Disease